Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban

Journal of Clinical Pharmacology
Jason MorellBrian F McBride

Abstract

Interpatient variability in the safety and efficacy of oral anticoagulation with warfarin presents several challenges to clinicians, thus underscoring the emergent need for new orally available anticoagulants with predictable pharmacokinetic and pharmacodynamic profiles and ability to target circulating clotting factors. Seven compounds including rivaroxaban, apixaban, betrixaban, and eribaxaban are orally available direct inhibitors of activated factor X currently in development for the prevention and treatment of venous thromboembolism and for thromboprophylaxis in patients with atrial fibrillation or following an acute coronary syndrome. At doses used in phase 2 and 3 clinical trials, rivaroxaban and apixaban demonstrated a predictable onset of effect, maximal plasma concentration, and half-life that was unaffected by age, renal, or hepatic disease. In clinical trials for the treatment and prevention of venous thromboembolism, rivaroxaban and apixaban produced equivalent or superior reductions in the development or progression of venous thromboembolism compared with either low molecular weight heparin or warfarin. Trials comparing the efficacy of rivaroxaban or apixaban to standard therapy for stroke prophylaxis in patients ...Continue Reading

References

Dec 1, 1992·Chest·E F Mammen
Mar 1, 1989·Journal of the American College of Cardiology·W J ManningP C Come
Jan 1, 1995·Chest·C A Wagenvoort
Feb 24, 1997·Archives of Internal Medicine·J WhittleL N Venditti
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·K KamataS H Kim
Apr 3, 2002·JAMA : the Journal of the American Medical Association·Mitchell K HigashiAllan E Rettie
Sep 12, 2003·The New England Journal of Medicine·Elaine M HylekDaniel E Singer
Dec 4, 2003·JAMA : the Journal of the American Medical Association·Alan S GoDaniel E Singer
Apr 17, 2004·Journal of Thrombosis and Thrombolysis·Eleni Hatzinikolaou-KotsakouDimitrios I Hatseras
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Dagmar KubitzaGeorg Wensing
Jan 13, 2006·Circulation·Thomas ThomUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jan 18, 2006·Journal of Thrombosis and Haemostasis : JTH·B I ErikssonUNKNOWN ODIXa-HIP Study Investigators
Nov 15, 2006·British Journal of Clinical Pharmacology·Dagmar KubitzaMichael Zuehlsdorf
Jun 29, 2007·International Journal of Clinical Pharmacology and Therapeutics·W MueckM Zuehlsdorf
Jul 17, 2007·Seminars in Thrombosis and Hemostasis·Volker LauxFrank Misselwitz
Mar 7, 2008·The New England Journal of Medicine·Ute I SchwarzC Michael Stein
Jun 11, 2008·Journal of Thrombosis and Haemostasis : JTH·UNKNOWN Botticelli Investigators, Writing CommitteA Segers
Jun 27, 2008·The New England Journal of Medicine·Bengt I ErikssonUNKNOWN RECORD1 Study Group
Jun 27, 2008·The New England Journal of Medicine·Michael R LassenUNKNOWN RECORD3 Investigators

❮ Previous
Next ❯

Citations

Feb 20, 2016·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Dagmar KubitzaFrank Misselwitz
Apr 5, 2012·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Yu Chen BarrettRobert M Knabb
Oct 16, 2010·Journal of Thrombosis and Haemostasis : JTH·A HillarpT L Lindahl
Jun 27, 2012·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Elena I SinauridzeFazoil I Ataullakhanov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Related Papers

JAMA : the Journal of the American Medical Association
S M ParnassA D Ivankovich
BMJ : British Medical Journal
J PalaceC Clough
The American Journal of the Medical Sciences
M OdehA Oliven
© 2021 Meta ULC. All rights reserved